Renalytix plc
("Renalytix" or the "Company")
PDMR Dealing
LONDON and SALT LAKE CITY, 13 June 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that the Board have granted Joel Jung, the interim Chief Financial Officer, options over 60,000 ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") ("Share Options").
The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £0.1625 per Ordinary Share, being the closing price of the shares on the 11 June 2024.
One fourth (1/4th) of the Share Options shall vest three months after the vesting commencement date, and 1/9th of the remaining number of Share Options shall vest monthly thereafter, subject to continuity of service as of each such date, save that the Option shall vest and be exercisable in full in connection with a change in control.
For further information, please contact:
| Renalytix plc | |
| James McCullough, CEO | Via Walbrook PR |
| |
|
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 |
| Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
|
| |
|
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 |
| Gary Clarence / Shalin Bhamra |
|
| | |
| Walbrook PR Limited Paul McManus / Alice Woodings / Charlotte Edgar | Tel: 020 7933 8780 or renalytix@walbrookpr.com Mob: 07980 541 893 / 07407 804 654 / 07884 664 686 |
| | |
| CapComm Partners | |
| Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Joel Jung | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Interim Chief Financial Officer | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| Renalytix plc | |||
| b)
| LEI | 213800NTOH3FK3WER551 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company | |||
| | | ||||
| Identification code | GB00BYWL4Y04 | ||||
| | | ||||
| b)
| Nature of the transaction
| Grant of options over shares | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | £0.1625 | 60,000 | | |
| | | | | | |
| d)
| Aggregated information |
| |||
| | | ||||
| - Aggregated volume | 60,000 | ||||
| | | ||||
| - Price | £9,750 | ||||
| | | ||||
| e)
| Date of the transaction
| 11 June 2024 | |||
| f)
| Place of the transaction
| Outside of trading venue - off market | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
